FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2039691757> ?p ?o ?g. }

• W2039691757 endingPage "490" @default.
• W2039691757 startingPage "479" @default.
• W2039691757 abstract "Purpose To describe long-term results of a multimodality strategy for stage III breast cancer utilizing neoadjuvant doxorubicin followed by mastectomy, CMF, and radiotherapy. Patients and methods Women with biopsy-proven, clinical stage III breast cancer and adequate organ function were eligible. Neoadjuvant doxorubicin (30 mg/m2 days 1–3, every 28 days for 4 cycles) was followed by mastectomy, in stable or responding patients. Sixteen weeks of postoperative CMF followed (continuous oral cyclophosphamide (2 mg/kg/day); methotrexate (0.7 mg/kg IV) and fluorouracil (12 mg/kg IV) weekly, weeks 1–8, and than biweekly, weeks 9–16). Radiation therapy followed adjuvant chemotherapy. Results Clinical response rate was 71% (79/111, 95% CI = 62–79%), with 19% complete clinical response. Pathologic complete response was 5% (95% CI = 2–11%). Median follow-up is 15.6 years. Half of the patients progressed by 2.2 years; half died by 5.4 years (range 6 months–15 years). The hazard of dying was greatest in the first 5 years after diagnosis and declined thereafter. Time to progression and overall survival were predicted by number of pathologically involved lymph nodes (TTP: HR [10 vs. 1 node] 2.40, 95% CI = 1.63–3.53, P < 0.0001; OS: HR 2.50, 95% CI = 1.74–3.58, P < 0.0001). Conclusions After multimodality treatment for locally advanced breast cancer, long-term survival was correlated with the number of pathologically positive lymph nodes, but not to clinical response. The hazard of death was highest during the first 5 years after diagnosis and declined thereafter, indicating a possible intermediate endpoint for future trials of neoadjuvant treatment." @default.
• W2039691757 created "2016-06-24" @default.
• W2039691757 creator A5001268619 @default.
• W2039691757 creator A5039225060 @default.
• W2039691757 creator A5047713528 @default.
• W2039691757 creator A5054042253 @default.
• W2039691757 creator A5059225709 @default.
• W2039691757 creator A5064138488 @default.
• W2039691757 creator A5069340619 @default.
• W2039691757 creator A5070245248 @default.
• W2039691757 creator A5073571977 @default.
• W2039691757 creator A5075481530 @default.
• W2039691757 creator A5079069209 @default.
• W2039691757 date "2008-02-28" @default.
• W2039691757 modified "2023-09-27" @default.
• W2039691757 title "Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)" @default.
• W2039691757 cites W1497080962 @default.
• W2039691757 cites W1824148142 @default.
• W2039691757 cites W1846747462 @default.
• W2039691757 cites W1860873974 @default.
• W2039691757 cites W1878812486 @default.
• W2039691757 cites W1915574909 @default.
• W2039691757 cites W1949597673 @default.
• W2039691757 cites W1955744924 @default.
• W2039691757 cites W1991488226 @default.
• W2039691757 cites W2015990146 @default.
• W2039691757 cites W2026686462 @default.
• W2039691757 cites W2057084727 @default.
• W2039691757 cites W2058085109 @default.
• W2039691757 cites W2081168956 @default.
• W2039691757 cites W2083803850 @default.
• W2039691757 cites W2086766680 @default.
• W2039691757 cites W2101760255 @default.
• W2039691757 cites W2109462843 @default.
• W2039691757 cites W2131915049 @default.
• W2039691757 cites W2133764807 @default.
• W2039691757 cites W2134915449 @default.
• W2039691757 cites W2135800076 @default.
• W2039691757 cites W2138021040 @default.
• W2039691757 cites W2138902655 @default.
• W2039691757 cites W2139510434 @default.
• W2039691757 cites W2140654333 @default.
• W2039691757 cites W2148252918 @default.
• W2039691757 cites W2151859419 @default.
• W2039691757 cites W2153158488 @default.
• W2039691757 cites W2159257820 @default.
• W2039691757 cites W2162760540 @default.
• W2039691757 cites W2167926320 @default.
• W2039691757 cites W2262955759 @default.
• W2039691757 cites W2329273512 @default.
• W2039691757 cites W4230868220 @default.
• W2039691757 cites W4239330499 @default.
• W2039691757 cites W4293241248 @default.
• W2039691757 cites W4360754311 @default.
• W2039691757 doi "https://doi.org/10.1007/s10549-008-9943-2" @default.
• W2039691757 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4217205" @default.
• W2039691757 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18306034" @default.
• W2039691757 hasPublicationYear "2008" @default.
• W2039691757 type Work @default.
• W2039691757 sameAs 2039691757 @default.
• W2039691757 citedByCount "13" @default.
• W2039691757 countsByYear W20396917572012 @default.
• W2039691757 countsByYear W20396917572013 @default.
• W2039691757 countsByYear W20396917572015 @default.
• W2039691757 countsByYear W20396917572018 @default.
• W2039691757 countsByYear W20396917572019 @default.
• W2039691757 countsByYear W20396917572021 @default.
• W2039691757 crossrefType "journal-article" @default.
• W2039691757 hasAuthorship W2039691757A5001268619 @default.
• W2039691757 hasAuthorship W2039691757A5039225060 @default.
• W2039691757 hasAuthorship W2039691757A5047713528 @default.
• W2039691757 hasAuthorship W2039691757A5054042253 @default.
• W2039691757 hasAuthorship W2039691757A5059225709 @default.
• W2039691757 hasAuthorship W2039691757A5064138488 @default.
• W2039691757 hasAuthorship W2039691757A5069340619 @default.
• W2039691757 hasAuthorship W2039691757A5070245248 @default.
• W2039691757 hasAuthorship W2039691757A5073571977 @default.
• W2039691757 hasAuthorship W2039691757A5075481530 @default.
• W2039691757 hasAuthorship W2039691757A5079069209 @default.
• W2039691757 hasBestOaLocation W20396917572 @default.
• W2039691757 hasConcept C121608353 @default.
• W2039691757 hasConcept C126322002 @default.
• W2039691757 hasConcept C141071460 @default.
• W2039691757 hasConcept C143998085 @default.
• W2039691757 hasConcept C207103383 @default.
• W2039691757 hasConcept C2776694085 @default.
• W2039691757 hasConcept C2776755627 @default.
• W2039691757 hasConcept C2777757722 @default.
• W2039691757 hasConcept C2780456651 @default.
• W2039691757 hasConcept C44249647 @default.
• W2039691757 hasConcept C509974204 @default.
• W2039691757 hasConcept C530470458 @default.
• W2039691757 hasConcept C71924100 @default.
• W2039691757 hasConcept C90924648 @default.
• W2039691757 hasConceptScore W2039691757C121608353 @default.
• W2039691757 hasConceptScore W2039691757C126322002 @default.
• W2039691757 hasConceptScore W2039691757C141071460 @default.
• W2039691757 hasConceptScore W2039691757C143998085 @default.

• next